Non Hodgkin Lymphoma (NHL) Market Report 2026

The non hodgkin lymphoma (nhl) market size has grown strongly in recent years. It will grow from $10.86 billion in 2025 to $11.73 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to rising incidence of nhl globally, advances in chemotherapy regimens, increasing healthcare expenditure, growing awareness of lymphatic cancers, expansion of oncology hospital infrastructure.

The non hodgkin lymphoma (nhl) market size is expected to see strong growth in the next few years. It will grow to $16.44 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to pipeline growth of targeted therapies, increasing approvals of biologics, rising adoption of personalized medicine, expanding access in emerging markets, growth in stem cell transplant procedures. Major trends in the forecast period include rising adoption of immunotherapy and targeted therapy, increasing use of combination treatment regimens, growing focus on early and accurate diagnosis, expansion of personalized treatment protocols, shift toward outpatient and home-based care models.

The high prevalence of non-Hodgkin lymphoma is anticipated to drive the growth of the non-Hodgkin lymphoma market in the coming years. Non-Hodgkin lymphoma is a type of cancer that originates in the lymphatic system, which plays a key role in the body’s immune defense. The prevalence of non-Hodgkin lymphoma indicates the number of people within a population who are currently diagnosed with or living with the disease at a given point in time. Treatment for non-Hodgkin lymphoma helps improve outcomes for individuals already affected by the condition by targeting and controlling cancerous cells. For example, in January 2023, according to the American Cancer Society, a US-based cancer health organization, non-Hodgkin lymphoma represents about 4% of all cancers and was expected to affect approximately 80,550 individuals in the United States in 2023, including 44,880 males and 35,670 females. The organization also estimated that around 20,180 deaths would occur in 2023 due to non-Hodgkin lymphoma. Therefore, the high prevalence of non-Hodgkin lymphoma is contributing to the expansion of the non-Hodgkin lymphoma market.

Key companies operating in the non-Hodgkin lymphoma market are increasingly concentrating on the introduction of advanced immunotherapies, such as Epcoritamab-bysp (EPKINLY), to strengthen their competitive position. Epcoritamab-bysp (EPKINLY) is an investigational subcutaneous immunotherapy developed to target CD20-expressing B-cell malignancies and has demonstrated encouraging outcomes in clinical trials, particularly in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. For instance, in November 2023, AbbVie Inc., a US-based pharmaceutical company, received a breakthrough therapy designation from the United States Food and Drug Administration for Epcoritamab-bysp (EPKINLY). This designation was granted for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more prior therapies. In addition, the European Medicines Agency validated a Type II application for epcoritamab (TEPKINLY) for the same indication. These developments were supported by previously reported results from the Phase 1/2 EPCORE NHL-1 clinical trial, which assessed the safety and preliminary efficacy of subcutaneous epcoritamab in 128 adult patients with relapsed, progressive, or refractory CD20-positive mature B-cell non-Hodgkin lymphoma, including follicular lymphoma.

In May 2023, Janssen Biotech Inc., a US-based developer of innovative pharmaceutical therapies, entered into a global collaboration and licensing agreement with Cellular Biomedicine Group involving an upfront payment of $245 million. Through this partnership, Janssen seeks to broaden its oncology portfolio and accelerate the development of next-generation chimeric antigen receptor T-cell therapies targeting CD19 and CD20 for relapsed or refractory B-cell malignancies, including diffuse large B-cell lymphoma, which is a major subtype of non-Hodgkin lymphoma. Cellular Biomedicine Group is a US-based biotechnology company focused on advanced cell therapies, including autologous CAR-T candidates that have demonstrated early-stage clinical activity in non-Hodgkin lymphoma.

Major companies operating in the non hodgkin lymphoma (nhl) market are Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non hodgkin lymphoma (nhl) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non hodgkin lymphoma (nhl) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the non hodgkin lymphoma market by increasing costs associated with imported biologics, active pharmaceutical ingredients, and advanced diagnostic equipment, impacting overall treatment affordability. The effects are most visible in immunotherapy and targeted therapy segments, with asia-pacific and emerging markets facing supply chain delays due to reliance on global manufacturing hubs. In response, pharmaceutical companies are localizing production, strengthening regional supply chains, and optimizing sourcing strategies. These shifts are also encouraging domestic manufacturing and long-term resilience in oncology drug development.

The non hodgkin lymphoma (nhl) market research report is one of a series of new reports that provides non hodgkin lymphoma (nhl) market statistics, including non hodgkin lymphoma (nhl) industry global market size, regional shares, competitors with a non hodgkin lymphoma (nhl) market share, detailed non hodgkin lymphoma (nhl) market segments, market trends and opportunities, and any further data you may need to thrive in the non hodgkin lymphoma (nhl) industry. This non hodgkin lymphoma (nhl) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Non-Hodgkin lymphoma is a type of cancer affecting the lymphatic system and is marked by the abnormal proliferation of white blood cells. It develops within the immune system component of the body’s lymphatic system, which plays a key role in fighting infections.

The primary types of non-Hodgkin lymphoma (NHL) include B-cell lymphoma and T-cell lymphoma. B-cell lymphoma refers to a group of cancers that arise from abnormal B lymphocytes in the immune system. Treatment for B-cell non-Hodgkin lymphoma generally involves a combination of therapies such as chemotherapy, immunotherapy, targeted therapy, radiation therapy, and stem cell transplantation. The range of treatments includes surgery, stem cell transplant, chemotherapy, immunotherapy, targeted therapy, and radiation therapy, which may be administered through different routes, including oral, parenteral, and others. These treatments are distributed through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and are used by various end users including hospitals, homecare facilities, specialty centers, and others.

The non-Hodgkin lymphoma market includes revenues earned by entities by treating aggressive lymphomas, indolent lymphomas, Burkitt lymphoma, lymphoma and leukemia, and B-cell lymphomas. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.